about
Efficacy and Safety of Vasopressin Receptor Antagonists for Euvolemic or Hypervolemic Hyponatremia: A Meta-AnalysisEffect of vasopressin antagonism on renal handling of sodium and water and central and brachial blood pressure during inhibition of the nitric oxide system in healthy subjects.Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.A copeptin-based classification of the osmoregulatory defects in the syndrome of inappropriate antidiuresisHyponatremia in the intensive care unit: How to avoid a Zugzwang situation?Effect of tolvaptan on renal water and sodium excretion and blood pressure during nitric oxide inhibition: a dose-response study in healthy subjectsHyponatremia and polyuria in an older womanVasopressin and the regulation of aquaporin-2Tolvaptan in the treatment of acute hyponatremia associated with acute kidney injury.Tolvaptan as a tool in renal physiologyHyponatremia and brain injury: historical and contemporary perspectives.Evaluation and management of hyponatraemia in children.Syndrome of inappropriate antidiuretic hormone secretion and cerebral/renal salt wasting syndrome: similarities and differencesNephrogenic syndrome of inappropriate antidiuresis secondary to an activating mutation in the arginine vasopressin receptor AVPR2.Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis.Tolvaptan for the treatment of hyponatremia and hypervolemia in patients with congestive heart failure.Vaptans for hyponatremia induced by psychogenic polydipsia.Asymmetric synthesis of drug-like spiro[chroman-3,3'-indolin]-2'-ones through aminal-catalysis.Management of hyponatremia in various clinical situations.Correction of Hyponatremia May Be a Treatment Stratification Biomarker: A Two-Stage Systematic Review and Meta-Analysis
P2860
Q26747663-79AF57A4-E0C4-4F5D-ACE3-BF14D9424443Q33838160-06DAA444-C704-4C87-AD34-9ECFF9382D30Q34257617-E7A48AE7-840D-4EB2-871B-A1834982E2B7Q34260031-F4BAE944-1BA2-46D4-9EBF-C752828C3120Q36265206-C7124E5E-5512-46D1-BC4F-CA8B013C871CQ36306545-DFA64A55-B328-425E-8B70-49A6EADC00D5Q37141979-839F4EE7-9936-4928-891B-7A2698101C2AQ37179035-46737B52-B169-4780-9BFA-ACA407EC72F3Q37555580-01731CE3-4DE5-4A20-B2F9-78EE03C05359Q37575572-C7E24F86-820C-4F4C-83F1-2355567C596BQ38065077-4824B9A2-1EE4-4B61-A88E-67380DB1F28BQ38215003-F67870F5-4E3B-4D41-8982-6E5C31E06127Q38346377-69F8D79E-7577-4C03-8A03-FC1CA9254F0DQ38682478-D2B9191E-8FFE-4DE3-928C-1000F8CD99F7Q38705713-E1C7DC91-1C52-451F-A6A3-07D00AB02D4BQ39456742-E3B381E9-E43D-441F-B8C5-7E59470D0CA2Q40935300-4AB2F9E4-C7D3-4447-9997-52732A7FE3B6Q46964568-235BC666-8726-40D4-8775-F94613E83E8CQ48838600-B8A485AB-EC66-43F2-9C41-48CB4B27F543Q58758423-C7760A79-5C1B-4E40-872F-690BDA9B98B5
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Vaptans for the treatment of hyponatremia.
@en
Vaptans for the treatment of hyponatremia.
@nl
type
label
Vaptans for the treatment of hyponatremia.
@en
Vaptans for the treatment of hyponatremia.
@nl
prefLabel
Vaptans for the treatment of hyponatremia.
@en
Vaptans for the treatment of hyponatremia.
@nl
P2860
P356
P1476
Vaptans for the treatment of hyponatremia.
@en
P2093
Gary L Robertson
P2860
P2888
P304
P356
10.1038/NRENDO.2010.229
P577
2011-02-01T00:00:00Z